HKUCTR-2922
Untitled Trial
An Open-label, Randomized Phase 3 Study of MK-6482 Versus Everolimus in Participants with Advanced Renal Cell Carcinoma That Has Progressed After Prior PD-1/L1 and VEGF-Targeted Therapies
Merck Sharp & Dohme (Asia) Ltd.·Phase 3·HKU CLINICAL TRIALS REGISTRY·drugRecruitment Completed
Study focus
- Disease/Condition
- Neoplasm
- Study type
- Interventional
- Intervention type
- drug
Sponsor & location
- Primary sponsor
- Merck Sharp & Dohme (Asia) Ltd.
- Location
- China
Timeline & enrollment
- Phase
- Phase 3
- Start date
- N/A
- End date
- Oct 15, 2021
ICD-10 classifications
NeoplasmsBenign neoplasmsIn situ neoplasmsPersonal history of other neoplasmsBenign neoplasm: Other specified sites
Data source
- Registry
- HKU CLINICAL TRIALS REGISTRY
- Trial ID
- HKUCTR-2922
- Type
- Non-Device Trial
About this record
Access comprehensive clinical trial information for HKUCTR-2922 through Pure Global AI's free database. This Phase 3 trial is sponsored by Merck Sharp & Dohme (Asia) Ltd. and is currently Recruitment Completed. The study focuses on Neoplasm.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to HKU CLINICAL TRIALS REGISTRY data, helping medical device and pharmaceutical companies navigate clinical research efficiently.